Intuitive Surgical CFO sells shares worth $61,651

Samath Jamie, Executive Vice President and Chief Financial Officer at Intuitive Surgical Inc . (NASDAQ:ISRG), a $200.8 billion medical technology company currently rated with "GREAT" financial health by InvestingPro, recently executed a series of stock transactions, according to a Form 4 filing with the Securities and Exchange Commission.

On February 26, Jamie sold 54 shares of Intuitive Surgical’s common stock at a price of $570.85 per share, totaling approximately $61,651. This sale was part of a pre-established trading plan under SEC Rule 10b5-1, which is set to expire on May 6, 2025. The transaction comes as the stock has delivered an impressive 50% return over the past year.

In addition to the sale, Jamie engaged in multiple acquisitions of common stock through the exercise of stock options. These transactions included acquiring 54 shares at an exercise price of $245.6 and another set of 54 shares at an exercise price of $347.4167. The total value of these acquisitions was $32,022.

Furthermore, Jamie disposed of 635 shares at a price of $573.74 per share to cover tax withholding obligations, with a total transaction value of $907,082.

Following these transactions, Jamie holds 4,890 shares of Intuitive Surgical’s common stock directly. With the company’s next earnings report scheduled for April 17, 2025, investors seeking deeper insights into ISRG’s valuation and 15+ additional ProTips can access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Intuitive Surgical reported strong fourth-quarter results, exceeding expectations with a 10% and 24% beat on revenue and earnings per share (EPS), respectively. The company’s procedure volume grew by 18% year-over-year, and it has projected a 13-16% increase for 2025. Piper Sandler raised its price target for Intuitive Surgical to $670, citing strong earnings and a positive outlook, while Bernstein maintained an Outperform rating with a $700 target, highlighting the company’s robust financial performance and potential for growth. RBC Capital Markets also reaffirmed an Outperform rating with a $641 price target, anticipating the launch of the da Vinci (EPA:SGEF) 5 system as a significant growth driver.

Truist Securities increased its price target to $666, maintaining a Buy rating and emphasizing the potential for revenue and EPS growth despite some anticipated challenges. Oppenheimer, however, retained a Perform rating, expressing concerns about market saturation and the valuation of Intuitive Surgical’s stock. Intuitive Surgical’s average selling price for its systems rose, driven by the da Vinci 5 system, with significant placements in the United States.

The company secured a €290 million distribution agreement to expand its presence in Italy, Spain, and Portugal, and received approval for new indications, enhancing its commercial efforts. Analysts from various firms have expressed confidence in Intuitive Surgical’s market position, with expectations for continued strong performance and growth in the coming years. The anticipated mid-year launch of the da Vinci 5 system is expected to play a pivotal role in the company’s future strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.